NERV RSI Chart
Last 7 days
6.3%
Last 30 days
2.8%
Last 90 days
-69.7%
Trailing 12 Months
-62.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2023 | luthringer remy | sold | -13,690 | 3.76 | -3,641 | ceo |
May 01, 2023 | luthringer remy | sold | -91,449 | 3.85 | -23,753 | ceo |
May 01, 2023 | race geoff | sold | -85,015 | 3.85 | -22,082 | president |
May 01, 2023 | ahlholm frederick w | sold | -16,038 | 4.48 | -3,580 | svp, cfo and secretary |
Apr 28, 2023 | luthringer remy | acquired | - | - | 88,077 | ceo |
Apr 28, 2023 | race geoff | acquired | - | - | 46,987 | president |
Apr 28, 2023 | ahlholm frederick w | acquired | - | - | 19,843 | svp, cfo and secretary |
Dec 01, 2021 | kupfer david | sold | -48,958 | 0.88 | -55,635 | - |
Dec 16, 2020 | race geoff | sold | -16,341 | 2.64 | -6,190 | evp, cfo & cbo |
Dec 16, 2020 | ahlholm frederick w | sold | -4,870 | 2.64 | -1,845 | svp, chief accounting officer |
Which funds bought or sold NERV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | -58,973 | 42,619 | -% |
May 15, 2024 | MORGAN STANLEY | added | 70.97 | -10,931 | 27,728 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -2.34 | -465 | 322 | -% |
May 15, 2024 | Anchor Investment Management, LLC | unchanged | - | -43.00 | 31.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 201 | 2,222 | 10,586 | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -357 | 258 | -% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | added | 54.14 | -140,479 | 257,082 | 0.02% |
May 15, 2024 | Royal Bank of Canada | added | 11.13 | -2,000 | 1,000 | -% |
May 14, 2024 | NORTHERN TRUST CORP | reduced | -7.6 | -94,102 | 59,563 | -% |
May 14, 2024 | FEDERATED HERMES, INC. | unchanged | - | -4,824,050 | 3,486,290 | 0.01% |
Unveiling Minerva Neurosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Minerva Neurosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Minerva Neurosciences Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -11.2% | 51.00 | 57.00 | 63.00 | 67.00 | 52.00 | 55.00 | 60.00 | 65.00 | 71.00 | 77.00 | 98.00 | 105 | 112 | 58.00 | 65.00 | 66.00 | 69.00 | 77.00 | 111 | 120 | 130 |
Current Assets | -15.2% | 36.00 | 42.00 | 48.00 | 52.00 | 37.00 | 40.00 | 45.00 | 50.00 | 56.00 | 62.00 | 67.00 | 75.00 | 82.00 | 27.00 | 35.00 | 36.00 | 38.00 | 47.00 | 61.00 | 71.00 | 80.00 |
Cash Equivalents | -14.7% | 35.00 | 41.00 | 47.00 | 52.00 | 36.00 | 36.00 | 40.00 | 50.00 | 55.00 | 61.00 | 66.00 | 74.00 | 80.00 | 25.00 | 33.00 | 32.00 | 30.00 | 21.00 | 38.00 | 28.00 | 31.00 |
Net PPE | -12.5% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | 0% | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 | 15.00 |
Liabilities | 2.0% | 87.00 | 85.00 | 83.00 | 80.00 | 78.00 | 75.00 | 74.00 | 73.00 | 71.00 | 69.00 | 69.00 | 69.00 | 66.00 | 5.00 | 7.00 | 9.00 | 50.00 | 50.00 | 55.00 | 53.00 | 52.00 |
Current Liabilities | -15.3% | 3.00 | 3.00 | 3.00 | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 5.00 | 7.00 | 7.00 | 7.00 | 10.00 | 8.00 | 7.00 |
Shareholder's Equity | -28.6% | -36.59 | -28.46 | - | - | -26.62 | -20.02 | - | - | - | 8.00 | 28.00 | 36.00 | 45.00 | 53.00 | 58.00 | 57.00 | 19.00 | 28.00 | 56.00 | 67.00 | 77.00 |
Retained Earnings | -2.2% | -405 | -396 | -387 | -379 | -373 | -366 | -360 | -353 | -344 | -334 | -313 | -304 | -344 | -284 | -277 | -304 | -298 | -286 | -256 | -242 | -230 |
Additional Paid-In Capital | 0.1% | 369 | 368 | 368 | 367 | 347 | 347 | 346 | 345 | 344 | 343 | 341 | 340 | 339 | 337 | 335 | 326 | 318 | 315 | 312 | 310 | 308 |
Shares Outstanding | 0% | 7.00 | 7.00 | 7.00 | 7.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 37.00 | - | - | - | 17.00 | - | - | - | 96.00 | - | - | - | 141 | - | - | - | 211 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -1.8% | -6,100 | -5,991 | -4,806 | -3,871 | -115 | -4,110 | -9,533 | -5,192 | -5,808 | -4,833 | -8,626 | -5,924 | -5,217 | -7,158 | -9,871 | -7,589 | -9,202 | -14,180 | -9,521 | -10,129 | -9,600 |
Share Based Compensation | -28.2% | 439 | 611 | 372 | 609 | 376 | 948 | 1,037 | 1,072 | 1,053 | 1,204 | 1,115 | 1,384 | 1,516 | 1,965 | 2,056 | 3,485 | 2,198 | 2,170 | 2,221 | 2,320 | 2,462 |
Cashflow From Investing | - | - | - | - | - | - | -16.33 | - | - | - | - | - | - | - | - | 3,000 | 4,500 | 17,028 | -2,312 | 19,582 | 7,366 | -10,551 |
Cashflow From Financing | - | - | - | -86.69 | 19,690 | - | - | - | - | - | - | - | - | 60,000 | - | 7,135 | 5,305 | 798 | -1* | - | - | 525 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Expenses | ||
Research and development | $ 4,167,287 | $ 2,653,553 |
General and administrative | 2,514,676 | 2,694,965 |
Total expenses | 6,681,963 | 5,348,518 |
Loss from operations | (6,681,963) | (5,348,518) |
Foreign exchange gains (losses) | 5,493 | (8,686) |
Investment income | 357,908 | 364,218 |
Non-cash interest expense for the sale of future royalties | (2,250,243) | (1,977,426) |
Net loss | $ (8,568,805) | $ (6,970,412) |
Net loss per share, basic | $ (1.13) | $ (1.31) |
Net loss per share, diluted | $ (1.13) | $ (1.31) |
Weighted average shares outstanding, basic | 7,568,981 | 5,340,193 |
Weighted average shares outstanding, diluted | 7,568,981 | 5,340,193 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 34,818,304 | $ 40,912,575 |
Restricted cash | 100,000 | 100,000 |
Prepaid expenses and other current assets | 702,546 | 989,865 |
Total current assets | 35,620,850 | 42,002,440 |
Equipment, net | 9,524 | 10,884 |
Capitalized software, net | 10,642 | 17,027 |
Goodwill | 14,869,399 | 14,869,399 |
Total assets | 50,510,415 | 56,899,750 |
Current liabilities | ||
Accounts payable | 1,435,568 | 1,805,320 |
Accrued expenses and other current liabilities | 1,395,227 | 1,535,097 |
Total current liabilities | 2,830,795 | 3,340,417 |
Liability related to the sale of future royalties | 84,267,066 | 82,016,823 |
Total liabilities | 87,097,861 | 85,357,240 |
Commitments and contingencies (Note 8) | ||
Stockholders' deficit | ||
Preferred stock; $0.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock; $0.0001 par value; 125,000,000 shares authorized; 6,993,406 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 699 | 699 |
Additional paid-in capital | 368,796,088 | 368,357,239 |
Accumulated deficit | (405,384,233) | (396,815,428) |
Total stockholders' deficit | (36,587,446) | (28,457,490) |
Total liabilities and stockholders' deficit | $ 50,510,415 | $ 56,899,750 |